Table 1.
Comparative Risks of Weight Gain and Extrapyramidal Symptoms With Typical and Atypical Antipsychotic Agents2
| Drug | Weight Gain | Extrapyramidal Symptoms |
|---|---|---|
| Typical Antipsychotics (First-Generation Antipsychotics) | ||
| Chlorpromazine (Thorazine) | ++ | +++ |
| Fluphenazine (Prolixin) | + | ++++ |
| Haloperidol (Haldol) | + | ++++ |
| Perphenazine (Trilafon) | + | ++++ |
| Thioridazine (Mellaril) | + | +++ |
| Thiothixene (Navane) | + | ++++ |
| Atypical Antipsychotics (Second-Generation Antipsychotics) | ||
| Aripiprazole (Abilify) | + | + |
| Asenapine (Saphris) | + | ++ |
| Clozapine (Clozaril) | ++++ | + |
| Iloperidone (Fanapt) | ++ | ± |
| Lurasidone (Latuda) | ± | + |
| Olanzapine (Zyprexa) | ++++ | ++ |
| Paliperidone (Invega) | ++ | ++ |
| Quetiapine (Seroquel) | ++ | + |
| Risperidone (Risperdal) | ++ | ++ |
| Ziprasidone (Geodon) | + | ++ |
± = negligible risk; + = low risk; ++ = moderate risk; +++ = moderately high risk; ++++ = high risk